NCT05294055View on ClinicalTrials.gov

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Multiple MyelomaLymphoma
Interventions
DRUG

Etoposide

Etoposide 1.5-1.8g/m2, single dose

DRUG

Cyclophosphamide

Cyclophosphamide 50mg/kg or 2g/m2, for 2 days

DRUG

Mecapegfilgrastim, day 2

Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy

DRUG

Mecapegfilgrastim, day 5

Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy

Trial Locations (7)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

Unknown

NOT_YET_RECRUITING

Anhui Provincial Hospital, Hefei

NOT_YET_RECRUITING

Peking University Third Hospital, Beijing

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

NOT_YET_RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

NOT_YET_RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER